Robert Turner (professor of medicine)

Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions

Retrieved on: 
Thursday, August 3, 2023

XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced today that Circulation: Cardiovascular Interventions has published results from the Phase 1 portion of its Phase 1/2 clinical trial (EXACT) of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.

Key Points: 
  • XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced today that Circulation: Cardiovascular Interventions has published results from the Phase 1 portion of its Phase 1/2 clinical trial (EXACT) of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.
  • “Patients with refractory angina are highly symptomatic and have an exceedingly poor quality of life.
  • “We would like to acknowledge all of the authors for their contributions in highlighting the promise of XC001 and thank patients and their families for their participation in the EXACT trial.
  • This established a dose of 1×1011 viral particles for future clinical research of XC001.

1 in 4 Americans at Risk for Fatty Liver Disease but Many Remain Undiagnosed

Retrieved on: 
Friday, May 20, 2022

FAIRFIELD, N.J., May 20, 2022 /PRNewswire/ -- The rise in obesity and diabetes in the United States is fueling a little understood yet life-threatening disease known as fatty liver disease, which affects an estimated 100 million people, many of whom are unaware they even have it. In its most severe form, fatty liver disease can progress to liver failure. To address this growing problem American Liver Foundation has announced a nationwide screening and public awareness campaign, Think Liver Think Life, launching this summer to test at-risk children and adults in all 50 states over the next five years.

Key Points: 
  • In its most severe form, fatty liver disease can progress to liver failure .
  • Those most at risk for fatty liver disease, also known as Nonalcoholic fatty liver disease (NAFLD), include people with type 2 diabetes, high BMI or obesity, and Hispanic and Asian communities.
  • Think Liver Think Life aims to help prevent and detect liver disease earlier, affect better management and treatment of liver disease, reduce stigma associated with liver disease, address health inequalities, advance changes in federal policy and increase funding for research.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Atonarp Announces Advisory Council of Science and Technology Experts to Boost Development of Digital Molecular Profiling

Retrieved on: 
Tuesday, November 16, 2021

"We are truly honored to have this highly distinguished group of experts on our Advisory Council," said Prakash Murthy, Atonarp Founder and CEO.

Key Points: 
  • "We are truly honored to have this highly distinguished group of experts on our Advisory Council," said Prakash Murthy, Atonarp Founder and CEO.
  • Atonarp has recently expanded its molecular profiling platform capabilities within industrial manufacturing and medical diagnostics.
  • "Its molecular profiling technology has huge potential across many areas, and I look forward to working with Atonarp and the council to maximize its impact."
  • The complete list of Atonarp's inaugural Advisory Council members is:
    Atonarp is a leading innovator in next-generation digital molecular profiling.

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

Retrieved on: 
Tuesday, October 19, 2021

The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcellas management team.

Key Points: 
  • The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcellas management team.
  • Additionally, the company announced today that it will now operate as Axcella Therapeutics.
  • Axcella uses its website, www.axcellatx.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions.